In obese mice, tirzepatide switched on brown fat even when they ate the same amount as untreated mice

What the research found

Study (animal). Marion Peyrou and colleagues at the University of Barcelona report in Biomedicine & Pharmacotherapy (doi 10.1016/j.biopha.2026.119057; ScienceDaily 26 September 2026, citing the university). Obese mice on a high-fat diet received tirzepatide and were compared with mice that did not get the agent but ate the same amount. With intake matched, tirzepatide still switched on brown adipose tissue, the fat that uses energy rather than mainly storing it. The authors link that to batokines and a greater capacity to burn metabolic energy. They say active brown fat uses glucose and fat and could help explain lower blood glucose, beyond the effect of eating less. Earlier attempts to switch on brown fat have stumbled on unwanted heart effects; the group says this agent did not show those effects in the mice. They warn that mouse and human fat, and responses to this agent, can differ, and they ask for human fat studies. Tirzepatide is a prescribed dual GIP and GLP-1 agent. A mouse result is not a reason to start, stop, or swap it. Educational notes. Not a substitute for clinician care.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at University of Barcelona / ScienceDaily